BioMedNewsBreaks

WednesdayMay 10, 2023 1:38 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) Announces Completion of Phase 1 Dosing in MS Clinical Trial

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, has completed dosing the first cohort of patients in its phase I clinical trial of Lucid-21-302 (Lucid-MS). According to the announcement, the study, which is being conducted by Lucid Psycheceuticals, the company’s wholly owned subsidiary, is the first-in-human study designed to evaluate Lucid-MS as a novel drug candidate for the treatment of multiple sclerosis (“MS”). A small molecule inhibitor of hypercitrullination, Lucid-MS is a patented first-in-class, new chemical…

Continue Reading

TuesdayMay 09, 2023 3:03 pm

BioMedNewsBreaks – Jupiter Wellness Inc. (NASDAQ: JUPW) Announces ‘Significant Milestone’ with Issuance of Patent

Jupiter Wellness (NASDAQ: JUPW), a wellness company focused on hair metabolism and skin therapies, has been issued a patent. The company stated that the patent, No. US 11,628,132, marked “a significant milestone in the development of innovative treatments for androgenetic alopecia, or hair loss. This foundational patent is a crucial component of the company's ongoing pursuit of the vast hair loss market.” According to the announcement, the technology covered by the patent focuses on increasing the efficacy of minoxidil, a widely used hair-loss treatment, used in a novel manner that could have the potential for a breakthrough solution for the…

Continue Reading

TuesdayMay 09, 2023 2:51 pm

BioMedNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’s Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has received a patent from the U.S. Patent and Trademark Office (“USPTO”). Titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders,” the patent claims cover the use of biomarkers in determining the efficacy of SILO’s portfolio drug SPC-15. SPC-15 is a targeted prophylactic treatment that uses ketamine compositions as a key component for treating stress-induced affective disorder or stress-induced psychopathology. According to the announcement, the company owns an option to license specific assets of which the patent forms a part. SPC-15…

Continue Reading

TuesdayMay 09, 2023 2:28 pm

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Doses Last Subject in Phase 1, Part B CYB004-E Trial

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, has completed dosing in part b of its three-part CYB004-E phase 1 trial. The study is designed to evaluate intravenous N,N-dimethyltryptamine (“IV DMT”) in healthy volunteers. The company also announced that it now plans to move forward with part C of the study, which involves the first-in-human dosing of its proprietary DMT molecule CYB004 and will evaluate IV bolus + infusion regimens of CYB004 in a crossover design. The company expects that findings from both parts of the…

Continue Reading

TuesdayMay 09, 2023 2:14 pm

BioMedNewsBreaks – Spok Holdings Inc. (NASDAQ: SPOK) to Present at Inaugural EF Hutton Global Conference

Spok Holdings (NASDAQ: SPOK) yesterday announced that Vincent D. Kelly, its president and chief executive officer, will be presenting at the Inaugural EF Hutton Global Conference. The two day, invitation-only event will be held on May 10-11, 2023, at the Plaza Hotel in the heart of New York City. The Inaugural conference will feature key executives from approximately 150 public and private companies to convey their unique stories to an extensive audience that includes institutional investors, high-net worth individuals, corporate clients and exclusive members of the press. To view the full press release, visit https://ibn.fm/UCwAa About Spok Inc. Spok, a…

Continue Reading

MondayMay 08, 2023 2:46 pm

BioMedNewsBreaks – FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) to Present at Sidoti Virtual Investor Conference

FSD Pharma (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders. The company today announced that Zeeshan Saeed, president and executive co-chairman, and Dr. Lakhsmi Kotra, executive director and CEO of Lucid Psycheceuticals, will present and host one-on-one meetings with investors at the Sidoti May Virtual Investor Conference. The event is slated to take place on May 10-11, 2023, with the presentation scheduled to begin at 3:15 p.m. ET on Thursday, May 11. In addition, FSD Pharma will…

Continue Reading

MondayMay 08, 2023 1:57 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Board Appointment of Pharma and Biotech Industry Veteran Dr. Bettina M. Cockroft

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced its appointment of Bettina M. Cockroft, M.D., M.B.A., to its board of directors. Dr. Cockroft, a well-established industry executive with over 30 years of experience in the biopharmaceutical industry with clinical development expertise across multiple therapeutic areas, will serve as an independent director. “On behalf of the CNS Pharmaceuticals board and management, we are thrilled to welcome Dr. Cockroft to the board. Her appointment adds deep scientific, clinical and operational expertise, and…

Continue Reading

MondayMay 08, 2023 9:00 am

BioMedNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Receives IND Clearance from FDA, Represents First Ever Natural Killer Immunotherapy Trial for a Particular Cancer

INmune Bio (NASDAQ: INMB), a clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease, announced that its Investigational New Drug (“IND”) application for INKmune(TM), a novel natural killer (“NK”) cell immunotherapy, has been cleared by the U.S. Food and Drug Administration (“FDA”) for a phase 1/2 open-label clinical trial for the treatment of metastatic castration-resistant prostate cancer (“mCRPC”). According to the announcement, this is the first NK immunotherapy trial in men with mCRPC, as far as the company is aware. The trial, which will begin enrolling patients later this year, will focus on determining short-…

Continue Reading

FridayMay 05, 2023 1:18 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Subsidiary Inks Stiff Person Syndrome Clinical Trial Agreement with Mayo Clinic

Aditxt (NASDAQ: ADTX), a global innovation company focused on therapeutics and technologies that monitor and modulate the immune system, and its subsidiary Adimune(TM) Inc. announced a clinical trial agreement with Mayo Clinic. The clinical trial, which is designed to advance clinical studies targeting autoimmune diseases of the central nervous system (“CNS”), is expected to begin this year with an estimated 10 to 15 patients, some of whom may also suffer from type-1 diabetes; the initial focus of the study will be on the autoimmune disease Stiff Person Syndrome (“SPS”). According to the announcement, Adimune, which was created to lead Aditxt’s immune…

Continue Reading

ThursdayMay 04, 2023 12:14 pm

BioMedNewsBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference

NanoViricides (NYSE American: NNVC), a clinical-stage global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, will be participating at the inaugural EF Hutton Global Conference. The two-day event is scheduled for May 10–11, 2023, in New York City. Company president Anil R. Diwan, PhD, will be presenting at the gathering; his presentation is scheduled May 10. The global conference is an elite, invitation-only event featuring key executives from some 150 public and private companies; company executives are invited to present the unique stories of their companies to institutional investors, high-net worth individuals, corporate clients and…

Continue Reading